A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Trial Profile

A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Results (n=754) evaluating exposure-efficacy and exposure-safety relationships of emtricitabine/rilpivirine/tenofovir alafenamide from this and one other phase III study, presented at the 24th Conference on Retroviruses and Opportunistic Infections.
    • 24 Oct 2016 The data from this trial were presented at the 2016 HIV Glasgow conference, as reported by a Gilead Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top